- Hypermobility and Early Development: Milestones, Motor Delay, and Predictions - 12 September 2026
- Fibromyalgia and Itching: Why It Happens, What the Science Actually Says, and What You Can Do About It - 9 September 2026
- Hypermobility in Children: Growing Pains, the Beighton Score, and What Actually Helps - 15 August 2026
This article is part of our comprehensive guide to POTS and dysautonomia.
Beta blockers are the drug most people with POTS get handed first, usually before anyone has explained what they actually do, why the dose matters, or whether they suit the kind of POTS you happen to have. You get a prescription, you take the tablet, and one of three things happens: your heart rate settles and you feel better, nothing much changes, or you end up flatter and more exhausted than you were before. The odd part is that all three of those outcomes can come from the same drug, and a fair share of the difference comes down to how much of it you’re taking, which is arguably the single most important thing to understand about this class of medication and the bit that almost nobody explains.
If you’ve been living with postural tachycardia syndrome for a while, you’ll know the feeling of being handed a medication with almost no context around it. You stand up, your heart races, you feel dizzy and wired and wrung out all at once, and someone suggests a beta blocker to bring the rate down, which is reasonable enough on the face of it. The trouble is that POTS is not one thing, beta blockers are not one dose, and the research on them is thinner and a fair bit more interesting than the leaflet lets on.
This article goes through what beta blockers actually do to a POTS body, and then works through the evidence as it stands rather than as the leaflet implies: the low dose versus high dose puzzle that trips up so many people, whether the choice between propranolol and the cardioselective options is settled or just assumed, who beta blockers genuinely suit, who they can make worse, and where they sit alongside the plainer work of salt, fluid, compression and graded exercise.
Two things are worth saying at the top though, as they shape everything below. The first is that the whole drug evidence base in POTS is small, short term and rarely broken down by subtype, so the honest answers here are narrower than you might expect [1]. The second is that no medication is licensed for POTS at all, anywhere, so every drug discussed here is being used off label, on the strength of a fairly modest body of work [1][22].
One quick note before we get going, this article is not medical advice and I’m not your prescriber. It’s a careful read of the evidence so you can have a better, more informed conversation with the people who do prescribe for you, and nothing here is a reason to start, stop or change a medication on your own.
What beta blockers actually do in POTS
Before we get to the medication, we need to understand why the heart rate does what it does in POTS, because this is the bit that gets missed constantly, and it’s the reason beta blockers help some people and flatten others.
When you stand up, gravity pulls a good chunk of your blood down into your legs and abdomen. In a body that handles this well, the blood vessels tighten, the return of blood to the heart holds up, and the heart rate rises just a little to keep everything ticking over. In POTS that compensation goes into overdrive, as the heart rate climbs by more than 30 beats per minute within ten minutes of standing, and it does so without the drop in blood pressure that would make it a simple faint [1]. In teenagers the threshold used is 40 beats per minute or more [2]. The racing heart is really the body’s clumsy attempt to solve a circulation problem, and it usually overshoots.
What drives that overshoot varies from person to person, and this is where most explanations go wrong by being far too tidy. Three mechanisms come up repeatedly, and they overlap rather than sorting people into neat boxes: a hyperadrenergic pattern where sympathetic drive is genuinely running hot, low blood volume, and a partial loss of the nerve supply that tightens blood vessels in the legs, which leaves blood pooling where it shouldn’t [1][3][4].
That matters for beta blockers specifically, because a beta blocker only acts on one of those three. Adrenaline and noradrenaline dock onto beta adrenergic receptors, and the beta 1 receptors sitting on the heart’s own pacemaker, the sinoatrial node, are the ones that crank the rate up. A beta blocker sits in front of those receptors so adrenaline and noradrenaline can’t rev the heart as hard, and the standing heart rate comes down [5]. Think of it as taking your foot slightly off an accelerator that’s been stuck too far down (analogies in physiology are always a bit rubbish, but that one holds up well enough).
On paper that sounds like exactly what you’d want, as racing heart plus a drug that slows the heart should equal problem solved. In practice it’s more complicated, for two reasons. The first is that a beta blocker addresses the sympathetic side of the picture and leaves low blood volume and venous pooling more or less untouched, so it isn’t aimed at every route into orthostatic symptoms [3]. The second is that slowing the heart is not the same as feeling better, and lowering the standing rate reliably is entirely compatible with the symptoms staying exactly where they were [5][6]. That gap between the number on the monitor and how a person actually feels is where the most useful finding about this drug class lives, and it’s the part most articles skip straight past.
The dose paradox: why less can beat more
In POTS, a low dose of propranolol works better than a high dose, even though the high dose slows the heart more, and honestly that’s the finding that should be printed on the box. It sounds completely back to front, so let me show you where it comes from!
In people with POTS, a single 20 mg dose of propranolol was tested against a placebo, and then that same 20 mg dose was tested against a much larger 80 mg one. The low dose brought the standing heart rate down and improved overall symptom burden, which is the result you’d expect. The 80 mg dose lowered the heart rate further, so if heart rate were the whole story it should have won comfortably, and it didn’t, as the larger dose delivered no further symptom benefit and there was a signal that it made symptoms worse [5].
The same pattern turns up when you measure capacity rather than symptoms, which matters enormously if you’re trying to rebuild any tolerance to activity at all. A single 20 mg dose lifted peak oxygen uptake in people with POTS, brought the runaway exercise heart rate under control, and appeared to do it by letting the heart fill better and push out a bigger volume with each beat [7]. That same low dose did nothing whatsoever for the healthy comparison volunteers, which tells you the benefit is specific to over revved POTS physiology rather than a general fitness boost. And when 80 mg of propranolol and 100 mg of metoprolol were tested in a separate group, neither improved exercise capacity despite lowering heart rate to a similar degree [7], so the low dose helps and the high dose really doesn’t.
Over a longer run the gap gets clearer still. Over three months, 80 mg of long acting propranolol brought the upright heart rate down to the level of healthy volunteers, which is about as complete a result as a rate lowering drug can produce, and quality of life didn’t move at all [8]. The number came down, in other words, and the life underneath it stayed pretty much exactly where it was.
The sensible reading of why more ends up being worse is that your heart rate on standing isn’t purely a nuisance, it’s doing a job. Some of that extra rate is compensating for the fact that less blood is coming back to the heart, and blood volume that’s already low leaves very little room to spare. Blunt the rate a little and you take the edge off the pointless overshoot, blunt it too hard and you cut into compensation the body genuinely needs, so the volume of blood leaving the heart falls [5][8]. It’s worth being careful about how far that explanation gets pushed though, as it’s an inference from the way the circulation behaves rather than something measured dose by dose in every person. What the evidence supports is that over blockade appears counterproductive. It doesn’t show that a specific dose starves a specific organ [5][10].
The current guidance puts the practical end of this almost as plainly. Higher doses and long acting formulations might lower the standing heart rate, but they’re described as generally ineffective for controlling symptoms, they aren’t recommended, and their side effects can include worse exercise tolerance and worse fatigue [2]. So more isn’t always more, it’s often just more side effects, unfortunately.
There’s a practical lesson buried in here, and it’s one worth taking to an appointment. If you were started on a beta blocker, felt flattened by it, and concluded that beta blockers aren’t for you, it’s genuinely possible the dose was too high for your physiology rather than the drug being wrong. The same guidance recommends starting at the low end, in the region of 10 to 20 mg of propranolol taken a few times a day, precisely because the aim is to shave the top off the tachycardia rather than to sedate the heart [2]. The temptation, for the person taking it and the prescriber both, is to assume that if a little helps then more will help more, and in this particular case the evidence says otherwise.
Propranolol, metoprolol, bisoprolol: does the choice matter?
Beta blockers aren’t all the same, and the differences aren’t just branding either. The main split is between the nonselective ones, like propranolol, which block beta 1 receptors on the heart and beta 2 receptors elsewhere in the body, and the cardioselective ones, like metoprolol and bisoprolol, which stick much more closely to the beta 1 receptors on the heart [9][10]. On the surface you’d think the cardioselective drugs would be the obvious pick for POTS, since the problem is a racing heart and those drugs target the heart more cleanly.
The guidance takes the opposite line, as far less is known about the benefit of cardioselective beta blockers in POTS and nonselective blockade with propranolol is preferred [2]. That’s a fair reflection of where the data sits, and it’s worth being precise about what it does and doesn’t mean, because this is a place where the confident version of the story runs well ahead of the evidence.
What’s true is that propranolol is by far the most directly studied beta blocker in POTS, as the low dose benefit, the exercise capacity findings and the dose paradox all come from propranolol specifically [3][5][7]. What isn’t true is that the evidence has shown propranolol to be the better drug. Metoprolol was only ever tested at a high dose, and a high dose of propranolol failed the same test alongside it, so that tells you something about high doses rather than something about cardioselectivity [7]. And when propranolol and bisoprolol were followed for three months, they came out comparable on orthostatic intolerance, on mood, and on quality of life, with neither pulling ahead [10].
The honest summary is narrower than the confident one, then. Propranolol has the strongest direct evidence base, and if it suits you the research is genuinely on your side. But the comparisons between beta blockers are few, small and short, and they don’t establish that propranolol is the better choice for everyone [1][11][12]. A cardioselective option is a reasonable thing to discuss, and you’re not stepping outside the evidence by doing it so much as stepping into a thinly mapped part of it.
That fits what people actually report, too. Spend any time in POTS communities and you’ll find someone who got nothing at all from propranolol and a real turnaround from bisoprolol, sitting right next to someone who says the exact opposite (which honestly happens a lot in this space), and it’s something people have argued about for years. That variability is exactly what you’d expect from a small comparative evidence base sitting on top of a condition that isn’t really one condition.
Who beta blockers actually suit, and who they don’t
POTS is an umbrella, and underneath it sit people whose bodies are doing quite different things. This matters more for beta blockers than for almost any other treatment, because the drug is aimed squarely at one of those mechanisms and not the others [3][13][14].
The group that tends to do best is the one often labelled hyperadrenergic POTS, where sympathetic drive is genuinely running hot. Suppressing that drive is the main pharmacological approach in this pattern, and a beta blocker is the usual tool for it [3][4]. Standing noradrenaline is the marker most often used to identify the group, with a level of 600 pg/mL or above taken as the cut off, and some people in the primary hyperadrenergic forms running from 1000 to 2000 pg/mL [15][16]. That same 600 pg/mL threshold has been used to select people into trials of rate lowering drugs [17][18]. If your POTS is being driven by an over active adrenaline system, a drug that blunts that system has something real to push against, and our piece on hyperadrenergic POTS goes through that pattern in detail.
The groups that tend to struggle are the other two. Where the dominant problem is low blood volume, the treatments that address it are volume expansion and graded exercise rather than sympathetic suppression, as there’s no excess sympathetic drive there to remove [3][4]. Where the dominant problem is impaired vasoconstriction and venous pooling, the logic points towards drugs that tighten blood vessels rather than drugs that slow the heart [4][14]. That distinction has actually been tested, as when midodrine, which works by tightening blood vessels, was compared against a placebo in the two subtypes side by side, it lowered both lying and standing heart rate and raised mean arterial pressure and calf vascular resistance in the neuropathic group, and did nothing that a placebo didn’t also do in the hyperadrenergic group [19].
The mechanism you’re treating decides whether the drug has anything much to work with.
If your circulation is already running on the low side, a drug whose job is to reduce the heart’s output can tip you from coping to not coping, and fatigue and low blood pressure are the two effects that show up most [15][16][6]. This particular strand is the weakest evidence in the whole piece, mind. It rests on mechanism, on side effect reporting and on clinical description rather than on trials that set out to test it in the low pressure group, so treat it as a reason for caution rather than a settled finding. The guidance reflects the same caution, steering towards the rate limiter ivabradine when someone has a tendency to low blood pressure, precisely because it slows the heart without the same blood pressure penalty [2]. That preference has some direct support: when ivabradine, propranolol and a placebo were compared in the same group of people with POTS, both drugs reduced the orthostatic tachycardia to a similar degree, but ivabradine raised systolic blood pressure more than propranolol did [6][18]. If you want the detail on that alternative, we’ve covered it in our review of ivabradine for POTS.
One safety point gets forgotten in the POTS conversation, and it needs stating carefully because the usual version of it is far too broad. Nonselective beta blockers like propranolol block beta 2 receptors in the airways as well as the beta 1 receptors on the heart, and blocking airway receptors can provoke bronchospasm. That’s a real concern rather than a theoretical one, and it’s why bronchospasm and poorly controlled asthma were exclusion criteria when ivabradine and propranolol were recently compared [6]. Comorbid asthma is named in the guidance as a reason to reach for ivabradine instead [2]. What doesn’t follow is that asthma rules out this whole class of drug, because cautious use of the cardioselective beta blockers is not automatically contraindicated in asthma or COPD, and the tolerability difference between selective and nonselective agents is the reason why [9]. So asthma is a reason to be specific about which beta blocker, at what dose, with what monitoring, rather than a reason to close the conversation down entirely.
All of which makes beta blockers a targeted tool rather than a blanket one. They’re aimed at the adrenaline driven end of POTS, they ask more of you at the low volume, low pressure end, and they need care around asthma. What they don’t come with is a rule that tells you in advance which side of that line you’re on, as most of the trials never sorted people by subtype at all, so the evidence supports individualised selection rather than a decision tree [12][14]. Working out which mechanism is doing most of the damage in your body, sometimes with a standing catecholamine measurement to see how hard the sympathetic system is actually working, is far more useful than arguing about beta blockers in the abstract.
Where beta blockers sit in the bigger picture
This is the part that rarely makes it into a five minute appointment, and it’s the elephant in the room for the whole conversation, really. At their best, beta blockers are one tool inside a much bigger stack, and they’re not the tool doing most of the work.
The guidance is consistent on this: getting fluid and salt up to expand blood volume, using compression to fight the pooling in your legs and abdomen, and rebuilding tolerance to being upright in a graded, sensible way all come before or alongside medication rather than after it [1][2][13][20]. We’ve written about the volume side in detail in our guides to POTS and salt and compression garments for POTS and hypermobility, because those levers are genuinely powerful and cost almost nothing (which, set against what a year of the fancy electrolyte sachets costs, matters more than it sounds).
Exercise deserves a special mention here, as the head to head puts beta blockers in their place rather bluntly. Structured exercise training was set against propranolol in people with POTS over three months, and both brought the standing heart rate down, so on that one number they looked similar. On the things that actually matter to a life they were not similar at all: training improved quality of life and preserved the volume of blood the heart pushes out with each beat, and propranolol did neither [8]. If you’re going to put effort anywhere, the graded exercise and the volume work is where the biggest return lives, and the beta blocker is there to make that work more tolerable rather than to replace it.
Worth knowing too: the compression and the drug aren’t rivals. When compression of the abdomen was combined with beta blockade, it prevented the blood pressure drop that propranolol caused on its own, and the combination improved symptoms more than propranolol did alone [21]. That’s the shape of a sensible plan, where the plain measures make the medication safer and more useful instead of making it redundant.
The one detail most people get wrong when they try the exercise half of that is the starting position. Beginning upright, while your blood volume is low and your tolerance is poor, means fighting gravity and the deconditioning at the same time, and it usually ends in a crash and a conclusion that exercise isn’t possible for you. Starting horizontal or semi reclined removes the gravity problem while you build the capacity, which is the whole thrust of our article on the first step everyone misses with POTS and exercise.
Watch out for one wrinkle here, though. The same guidance that recommends low dose propranolol also warns that its side effects can worsen exercise tolerance and fatigue, and flags that this is particularly awkward for someone trying to carry out an exercise programme [2]. So a beta blocker can, in the wrong dose, actively undercut the treatment that helps most, which is a reason to keep the dose low, to notice whether the drug is helping you move more or move less, and to treat that as real information rather than a personal failing. If your resting numbers look calmer but you’re spending more of your life on the sofa, the drug is “working” and you aren’t, and that’s a question worth sitting with.
What the wider evidence actually shows
Step back from any single result and the whole body of evidence is, honestly, thinner than you’d hope for a drug this commonly prescribed. When every randomised comparison of POTS treatments was pulled together, it came to 21 trials covering around 750 people between them [1]. That is not a lot of people for a condition this widespread, and most of those trials were small and short. The evidence base isn’t yet strong enough to settle whether the mainstay drugs, beta blockers included, should be first line treatments, and large properly powered trials are still needed [1]. Longer term data is the biggest gap of all, as almost nothing here follows people for the years they’ll actually be taking the tablet [12][14].
Propranolol has most recently been put against ivabradine and a placebo in the same group of people, and both drugs brought the orthostatic tachycardia down to a similar degree, with no clear winner between them on rate, while ivabradine gave more support to blood pressure [6]. Fatigue, poorer sleep and lowered blood pressure came up as the side effects to watch for with propranolol [6]. All of which fits neatly with everything else: the two drugs are broadly in the same ballpark for slowing the heart, and the choice between them comes down to your subtype, your blood pressure and how you personally tolerate them [2][6].
Put all of that together and the picture is reasonably clear, even if the evidence underneath it is patchy. Low dose propranolol has the best supporting data of any beta blocker in POTS, it earns a genuine recommendation for the right person, and it can meaningfully help both the racing heart and exercise tolerance [2][5][7]. At the same time it isn’t a cure, it doesn’t outperform the fundamentals of volume and graded movement, and pushed too hard it turns on you [2][8]. That’s a useful if slightly deflating truth, and it’s a much better place to start a conversation with your prescriber than either blind faith or blanket rejection.
The bigger nervous system picture
It’s worth zooming out for a moment, because POTS rarely turns up on its own. It travels with hypermobility and Ehlers Danlos syndrome, with mast cell issues, and very often with a nervous system that’s been running in a high arousal, high alert state for a long time.
That last paragraph is a different kind of claim from the rest, mind. That POTS is a mixed, overlapping condition rather than one uniform syndrome is well established [3][13]. The specific overlaps with mast cell activation, with hypermobility, and with a chronically aroused nervous system are clinical description and pattern recognition, widely reported and matching what we see in the studios, and they aren’t established by the trial evidence here. Hold them accordingly.
What the heterogeneity does explain is why two people with the same heart rate numbers can have such different experiences of the same drug. A beta blocker calms one specific channel of an over active system, so whether that helps you a lot, a little, or not at all depends on how much of your trouble is running through that particular channel. If the arousal side rings true, our article on why hypermobile bodies are wired for anxiety digs into the mechanism, and our overview of the POTS, EDS and mast cell trifecta covers how these systems feed one another. For the fuller view of how POTS is understood and managed now, our complete guide to POTS and dysautonomia is the place to start, and it’s worth reading our breakdown of what the 2026 POTS guidelines changed alongside it.
Frequently asked questions
Are beta blockers a cure for POTS?
No, and I’d be wary of anyone who framed them that way. A beta blocker can take the top off the racing heart and, at a sensible low dose, make activity more tolerable, but it doesn’t fix the underlying circulation problem, and no drug is licensed for POTS in the first place [1][5]. The measures that shift POTS most reliably are the unglamorous ones: expanding blood volume with salt and fluid, using compression, and rebuilding tolerance to being upright through graded exercise. Structured training came out ahead of propranolol on quality of life [2][8]. Think of a beta blocker as something that can make the real work more doable rather than a replacement for it.
Why do beta blockers make me so tired?
Fatigue and reduced exercise tolerance are among the most commonly reported effects of this drug class [2][6], and often it comes down to dose. A dose higher than you need slows the heart enough to cut into the output your body relies on, and the result is feeling flat and wiped out, which is exactly the pattern in the dosing work, where the larger dose lowered heart rate more and left people no better, with a hint of worse [5][7]. If a beta blocker is flattening you, that’s real information worth taking back to your prescriber, and a lower dose is often the answer rather than abandoning the drug altogether.
Which beta blocker is best for POTS?
Low dose propranolol is the reasonable default, because it’s the one with the most direct trial data behind it and the guidance prefers nonselective blockade over the cardioselective options [2][5][7]. What the evidence does not show is that propranolol is actually the better drug. Followed over three months, propranolol and bisoprolol came out comparable on symptoms and on quality of life [10], and the comparisons between agents are too few and too short to settle a first choice for everybody [1][11]. So if propranolol suits you, stay with it, and if it doesn’t, a cardioselective option is a legitimate thing to discuss rather than a step down.
Can I take beta blockers if my blood pressure is low?
This is where beta blockers can cause real trouble, and it’s a conversation for your prescriber rather than something to sort out alone. Because a beta blocker reduces the heart’s output, it can push an already low blood pressure lower, which is why some people feel worse on them [2][15]. That reasoning rests more on mechanism and reported side effects than on trials designed to test it, so it’s a caution rather than a rule. For people with a tendency to low blood pressure the guidance leans towards ivabradine, which lowered heart rate while supporting systolic pressure better than propranolol when the two were compared [2][6]. If your POTS runs alongside low blood pressure or a lot of pooling, make sure whoever prescribes for you knows, as it genuinely changes which medication is sensible.
Do I have to take beta blockers forever?
Not necessarily. Plenty of people use a beta blocker as a bridge, something that makes the early stages of rebuilding tolerance more manageable, and find their reliance on it drops as volume, fitness and overall stability improve. Training improved upright circulation and quality of life across three months, which supports that direction of travel [8]. Prognosis and response both vary a lot from person to person, so there’s no standard answer on how long anyone needs it [1][13]. Coming off any heart medication should be done gradually and with your prescriber, never abruptly on your own, but for many people the goal is to need less of it over time rather than to be tied to the tablet indefinitely.
The honest bottom line
If you take one thing from this, let it be the dose lesson. A low dose of propranolol has real evidence behind it for the right person with POTS, and it can genuinely help both the racing heart and your capacity to move, but a bigger dose is not a better one, and pushing it too hard is the fastest way to end up flatter and more exhausted [2][5][7]. Beyond that, beta blockers are one tool in a stack, and they’re not the tool doing the heavy lifting. The volume work, the compression, and above all the unhurried, graded rebuilding of your tolerance to being upright are what shift the condition most, and the medication is there to make that work more bearable [8][21].
The second thing worth carrying out of here is how much of this is still unsettled. Which beta blocker, at what dose, for which pattern of POTS, over what timescale: those questions have small, short answers at best, and in places no answer at all [1][12]. None of which is a reason for despair, it’s a reason to be sceptical of anyone who sounds certain about it, a leaflet included.
If you’re already on a beta blocker, none of this is me telling you to stop, it’s a reason to have an honest conversation with your prescriber about whether it’s helping you function, whether the dose is right rather than simply high, and whether your particular flavour of POTS is one this drug actually suits. And if you’ve been let down by one in the past, it’s worth knowing that a bad experience often says more about the dose or the subtype than it does about the whole class of medication.
The Fibro Guy
